Latest & greatest articles for urinary tract infection

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on urinary tract infection or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on urinary tract infection and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for urinary tract infection

141. Role of urinary tract infection in non-schistosomiasis bladder cancer: protocol for a systematic review and planned meta-analysis

Role of urinary tract infection in non-schistosomiasis bladder cancer: protocol for a systematic review and planned meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2016 PROSPERO

142. Risk of adverse outcomes in pregnancy in women with bacteriuria or urinary tract infections

Risk of adverse outcomes in pregnancy in women with bacteriuria or urinary tract infections Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2016 PROSPERO

143. Effectiveness of antibiotic prophylaxis in cystoscopy to prevent urinary tract infection: a systematic review and meta-analysis

Effectiveness of antibiotic prophylaxis in cystoscopy to prevent urinary tract infection: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2016 PROSPERO

144. Systematic review and meta-analysis of the risk factors for multidrug resistant urinary tract infection

Systematic review and meta-analysis of the risk factors for multidrug resistant urinary tract infection Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2016 PROSPERO

145. Definitions of urinary tract infection after intravesical botulinum toxin injection

Definitions of urinary tract infection after intravesical botulinum toxin injection Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2016 PROSPERO

146. Systematic review and meta-analysis of the performance of the Sysmex UF-1000i (urinary white blood cell and bacteria counts) in the diagnosis of a urinary tract infection

Systematic review and meta-analysis of the performance of the Sysmex UF-1000i (urinary white blood cell and bacteria counts) in the diagnosis of a urinary tract infection Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2016 PROSPERO

147. Short versus long course antibiotic therapy for treating uncomplicated, symptomatic lower urinary tract infections in women

Short versus long course antibiotic therapy for treating uncomplicated, symptomatic lower urinary tract infections in women Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2016 PROSPERO

148. Etiological relevance of urinary tract infection in jaundice in the first year of life

Etiological relevance of urinary tract infection in jaundice in the first year of life Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2016 PROSPERO

149. Effectiveness of trimethoprim/sulfamethoxazole on urinary tract infections prophylaxis in kidney transplant recipient patients: a systematic review and meta-analysis protocol

Effectiveness of trimethoprim/sulfamethoxazole on urinary tract infections prophylaxis in kidney transplant recipient patients: a systematic review and meta-analysis protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2016 PROSPERO

150. Lower urinary tract symptoms and urinary tract infections in children with functional constipation: a systematic review

Lower urinary tract symptoms and urinary tract infections in children with functional constipation: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2016 PROSPERO

151. Antimicrobial agents for preventing urinary tract infections in patients undergoing cystoscopy [Cochrane Protocol]

Antimicrobial agents for preventing urinary tract infections in patients undergoing cystoscopy [Cochrane Protocol] Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2016 PROSPERO

152. Optimal dosage and duration of pivmecillinam for the treatment of urinary tract infections

Optimal dosage and duration of pivmecillinam for the treatment of urinary tract infections Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address

2016 PROSPERO

153. Urinary Tract Infection

Urinary Tract Infection 1 Quality Department Guidelines for Clinical Care Ambulatory Urinary Tract Infection Guideline Team Team Leader Steven E Gradwohl, MD General Medicine Team Members Catherine M Bettcher, MD Family Medicine Carol E Chenoweth, MD Infectious Diseases R Van Harrison, PhD Medical Education Lauren B Zoschnick, MD Obstetrics & Gynecology Initial Release June, 1999 Most Recent Major Update May, 2011 Interim/Minor Revision September, 2016 Ambulatory Clinical Guidelines Oversight (...) Grant M Greenberg, MD, MA, MHSA R Van Harrison, PhD Literature search service Taubman Health Sciences Library Urinary Tract Infection Patient population: Adult women with uncomplicated UTI Objective: Implement a cost-effective strategy for uncomplicated UTI in women Key Points ¦ Diagnosis • History. Diagnosis is made primarily by history. In women with dysuria and frequency, in the absence of vaginitis, the diagnosis is UTI 80% of the time [IC*]. • Phone triage. In women with prior history

2016 University of Michigan Health System

155. Probiotics for preventing urinary tract infections in adults and children. Full Text available with Trip Pro

Probiotics for preventing urinary tract infections in adults and children. Urinary tract infection (UTI) is a common bacterial infection that can lead to significant morbidity including stricture, abscess formation, fistula, bacteraemia, sepsis, pyelonephritis and kidney dysfunction. Mortality rates are reported to be as high as 1% in men and 3% in women due to development of pyelonephritis. Because probiotic therapy is readily available without a prescription, a review of their efficacy

2015 Cochrane

156. Fosfomycin (Fomicyt) - for the treatment of the following infections in adults and children including neonates: acute osteomyelitis; complicated urinary tract infections; nosocomial lower respiratory tract infections; bacterial meningitis; and bacteraemia

Fosfomycin (Fomicyt) - for the treatment of the following infections in adults and children including neonates: acute osteomyelitis; complicated urinary tract infections; nosocomial lower respiratory tract infections; bacterial meningitis; and bacteraemia Final Appraisal Recommendation Advice No: 3015 – October 2015 Fosfomycin (Fomicyt ® ) 40 mg/ml powder for solution for infusion Limited submission by Nordic Pharma UK Ltd Additional note(s): ? Fosfomycin (Fomicyt ® ) is appropriate (...) within NHS Wales for the treatment of the following infections in adults and children including neonates: acute osteomyelitis; complicated urinary tract infections; nosocomial lower respiratory tract infections; bacterial meningitis; and bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above. Fosfomycin (Fomicyt ® ) should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended

2015 All Wales Medicines Strategy Group

157. Interventions for preventing recurrent urinary tract infection during pregnancy. Full Text available with Trip Pro

Interventions for preventing recurrent urinary tract infection during pregnancy. Recurrent urinary tract infections (RUTI) are common in women who are pregnant and may cause serious adverse pregnancy outcomes for both mother and child including preterm birth and small-for-gestational-age babies. Interventions used to prevent RUTI in women who are pregnant can be pharmacological (antibiotics) or non-pharmacological (cranberry products, acupuncture, probiotics and behavioural modifications). So

2015 Cochrane

158. Chinese herbal medicine for treating recurrent urinary tract infections in women. Full Text available with Trip Pro

Chinese herbal medicine for treating recurrent urinary tract infections in women. Acute urinary tract infection (UTI) is a common bacterial infection that affects 40% to 50% of women. Between 20% and 30% of women who have had a UTI will experience a recurrence, and around 25% will develop ongoing recurrent episodes with implications for individual well-being and healthcare costs. Prophylactic antibiotics can prevent recurrent UTIs but there are growing concerns about microbial resistance, side (...) using relative risk (RR) for dichotomous outcomes with 95% confidence intervals (CI).We included seven RCTs that involved a total of 542 women; of these, five recruited post-menopausal women (aged from 56 to 70 years) (422 women). We assessed all studies to be at high risk of bias. Meta-analyses comparing the overall effectiveness of treatments during acute phases of infection and rates of recurrence were conducted. Analysis of three studies involving 282 women that looked at CHM versus antibiotics

2015 Cochrane

159. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). (Abstract)

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Treatment of complicated urinary-tract infections is challenging due to rising antimicrobial resistance. We assessed the efficacy and safety of ceftolozane-tazobactam, a novel antibacterial with Gram-negative activity, in the treatment of patients with complicated lower-urinary-tract infections (...) or pyelonephritis.ASPECT-cUTI was a randomised, double-blind, double-dummy, non-inferiority trial done in 209 centres in 25 countries. Between July, 2011, and September, 2013, hospital inpatients aged 18 years or older who had pyuria and a diagnosis of a complicated lower-urinary-tract infection or pyelonephritis were randomly assigned in a 1:1 ratio to receive intravenous 1·5 g ceftolozane-tazobactam every 8 h or intravenous high-dose (750 mg) levofloxacin once daily for 7 days. The randomisation schedule

2015 Lancet Controlled trial quality: predicted high

160. Treatment of Urinary Tract Infections in the Elderly

Treatment of Urinary Tract Infections in the Elderly Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along (...) . It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Treatment of Urinary Tract Infections in the Elderly: Clinical

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review